<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334564</url>
  </required_header>
  <id_info>
    <org_study_id>2015YWNL001</org_study_id>
    <nct_id>NCT04334564</nct_id>
  </id_info>
  <brief_title>Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome</brief_title>
  <official_title>Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome: a Randomized, Double-blind, Placebo Parallel Control, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Open Angle Glaucoma (POAG) is an eye disease that causes optic nerve damage, visual&#xD;
      field defect, and blindness caused by increased intraocular pressure. In recent years, many&#xD;
      studies have shown that ginkgo biloba extract has a protective effect on the visual function&#xD;
      of glaucoma patients. Studies have shown that Ginkgo biloba capsules can improve the visual&#xD;
      field damage of glaucoma controlled by intraocular pressure;Ginkgo biloba capsule can promote&#xD;
      the recovery of visual evoked potential of glaucoma controlled by intraocular pressure; the&#xD;
      improvement of visual field has a certain correlation with visual electrophysiological&#xD;
      recovery. The mechanism may be achieved by suppressing the influx of calcium ions and thereby&#xD;
      inhibiting the apoptosis of cells. Therefore, in this clinical study, effect of Ginkgo biloba&#xD;
      capsule on visual function of primary open-angle glaucoma with blood stasis syndrome was&#xD;
      evaluated by placebo as control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, the visual field, including MD, MS, LV, and vision score, are the&#xD;
      main efficacy indicators. HRT and visual electrophysiological examination are the secondary&#xD;
      efficacy indicators. Safety indicators based on laboratory tests and total frequency and&#xD;
      incidence of adverse events. To evaluate the effectiveness and safety of Ginkgo biloba&#xD;
      capsules for glaucoma patients with intraocular pressure control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean defect of visual field (MD)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Detection by humphrey visual field meter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fiber layer thickness (RNFL)</measure>
    <time_frame>After 12, 24, 36, and 48 weeks of treatment</time_frame>
    <description>Detection by optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">512</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>Test team</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba capsule</intervention_name>
    <description>Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.</description>
    <arm_group_label>Test team</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos were controls.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Accord with the diagnostic criteria of primary open-angle glaucoma.&#xD;
&#xD;
          -  2. Accord with the standard of blood stasis and collateralization syndrome in&#xD;
             traditional Chinese medicine (TCM).&#xD;
&#xD;
          -  3. Intraocular pressure ≤ 18mmHg&#xD;
&#xD;
          -  4. AGIS score of visual field defect ≥ 6 points and ≤ 17 points, cup to disc ratio &gt;&#xD;
             0.6, central corrected visual acuity ≥ 0.3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. The diagnoses of angle closure glaucoma, absolute glaucoma, glaucoma ciliary body&#xD;
             syndrome, high intraocular pressure (IOP) and secondary glaucoma.&#xD;
&#xD;
          -  2. Patients with various fundus diseases, such as retinal detachment, retinal vein&#xD;
             occlusion, retinal pigmented degeneration, blood or vascular diseases.&#xD;
&#xD;
          -  3. Complicated with cornea, iris, visible lens lesion, or one-eye patient.&#xD;
&#xD;
          -  4. Patients who need to use improved circulation, nutritional nerve drugs during the&#xD;
             trial.&#xD;
&#xD;
          -  5. Any eye surgery or laser therapy during the induction period.&#xD;
&#xD;
          -  6. Patients with a history of eye infection during the introduction period.&#xD;
&#xD;
          -  7. Complicated with severe liver and kidney diseases, or abnormal examination of liver&#xD;
             and kidney function (ALT,AST ≥ normal upper limit 1.5 times, SCr &gt; normal upper&#xD;
             limit).&#xD;
&#xD;
          -  8. Complicated with severe heart and lung diseases (such as bronchial asthma or&#xD;
             history of bronchial asthma, chronic obstructive pulmonary disease, bronchospasm,&#xD;
             respiratory failure, etc.), diabetes, advanced tumors, blood and hematopoietic system&#xD;
             diseases, or other serious or progressive diseases of the system.&#xD;
&#xD;
          -  9. A person who is prone to bleeding, or who has suffered severe bleeding during the&#xD;
             period of introduction.&#xD;
&#xD;
          -  10. Pregnant, lactating women or recent birth plans.&#xD;
&#xD;
          -  11. Other conditions considered inappropriate by the investigator.&#xD;
&#xD;
          -  12. Patients who participated in other clinical trials during the introduction period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Ge, M.D,Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Zhognshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chengguo Zuo, M.D,Ph.D</last_name>
    <phone>020-66615461</phone>
    <email>chengguozuo@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Ge, M.D,Ph.D</last_name>
    <phone>020-66615461</phone>
    <email>gejian@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhognshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengguo Zuo, M.D,Ph.D</last_name>
      <phone>02066615461</phone>
      <email>chengguozuo@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Ge, M.D,Ph.D</last_name>
      <phone>02066615461</phone>
      <email>gejian@mail.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Ginkgo biloba capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blind Loop Syndrome</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The archived documents and materials are not loaned. If the management department needs to access the original data, it should be agreed by the PI of the project.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

